Addressing healthcare issues in our region
Founded by leading biochemist Dr Charlie Bavington in 2005, GlycoMar is a marine natural products and drug discovery company.
It uses diverse organisms from the marine environment to develop new ingredients for products used in healthcare, cosmetics, and nutrition.
GlycoMar’s healthcare and pharmaceutical products are used to address issues such as eczema, rhinitis, asthma and inflammatory bowel disease; its cosmetic ingredients are used in the skincare market; and its nutraceutical ingredients are in demand from the supplements and functional food markets.
“We’re an R&D company that covers early stages from discovery through to product development. Beyond that we look to partner, or licence out,” explains Dr Bavington.
“In 2016, we set up Prasinotech, a joint venture with Norwegian technology company MicroA. We manufacture high-value polysaccharide products from microalgae – and we’re the first company in the world to do this. Production is sustainable and completely natural, using only light and carbon dioxide to cultivate the microalgae in seawater. Our first products, which between us we took from discovery right through to market, are Prasinoguard and PrasinoPS, active ingredients for use in cosmetic skincare.”
“HIE has helped us a lot over the years,” says Dr Bavington. “As a shareholder, they invested in the company with development grants and have generally been very positive and helpful in supporting our development. There’s been a lot of interaction and they’ve been willing to be creative. That’s starting to really pay off now.
“We’ve invested a lot and done a huge amount of R&D over the 12 years we’ve been going, and we’re in a strong position now with lots of intellectual property (IP). So the focus now is looking for new ways to use this IP in future products.”